Swedish Orphan Biovitrum AB (publ): Annette Clancy joins Sobi's Board of Directors

Annette Clancy joins Sobi's Board of Directors

Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General meeting (AGM) today
elected Annette Clancy to Sobi's Board of Directors. Ms. Clancy has over 30
years of experience in the Pharmaceutical and Biotechnology Industry, working in
a variety of roles in the US and UK. With Ms Clancy, Sobi's Board expands to
eight members with international experience in a wide variety of relevant
healthcare disciplines.

"I am delighted to welcome Annette to Sobi", said Bo Jesper Hansen, Chairman of
the Board at Sobi. "Annette's extensive experience from a variety of senior R &
D, commercial, and business development functions in the pharmaceutical industry
makes her a perfect addition to the Board. Annette's skills, knowledge and
experience will be invaluable to furthering the success of Sobi."

Annette Clancy was born 1954 and has a BSc Hons Pharmacology, from Bath
University UK. She is Chairman as well as Non-Executive Director of the Board in
Genable Technologies and ObsEva SA. Ms. Clancy was Head of Transactions and
Alliance Management at GlaxoSmithKline (GSK) where she was responsible for
executing major transactions ranging from early drug discovery partnerships, to
global commercial alliances and Mergers and Acquisitions. Since her retirement
from GSK in 2008, Ms. Clancy has been appointed as Non-Executive Board Director
to Silence Therapeutics plc. (2008-2012) and Clavis Pharma in Norway (2010-
2013).

Ms. Clancy also currently serves as Senior European Advisor to the
Biopharmaceutical Team of Frazier Healthcare Ventures, for whom she provides
strategic advice on both new and existing investments. Annette Clancy does not
hold any shares or options in Sobi. She is independent in relation to the
company and its management and in relation to the company's principal
shareholders.

The ordinary Board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen,
Lennart Johansson, Helena Saxon, Hans GCP Schikan and Hans Wigzell were re-
elected and Bo Jesper Hansen was re-elected chairman of the Board.

---

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.



For more information please contact

 Media relations          Investor relations

 Oskar Bosson,            Jörgen Winroth,

 Head of Communications   Vice President, Head of Investor Relations

 T: +46 70 410 71 80      T: +1 347-224-0819, +1 2125790506, +46 8 697 2135

 oskar.bosson@sobi.com    jorgen.winroth@sobi.com



 The information was released for public distribution on May 8, 2014 at
18:30 CET.


[HUG#1783944]